United States Archives - LVIS Corporation

Announcing the U.S. and Korea release of NeuroMatch®. Learn more:

United States Korea

LVIS NeuroMatch selected as a Finalist for the 2026 Edison Best New Product Awards

Closing the EEG Bottleneck: How AI-Driven EEG Signal Analysis Is Reshaping Neurological Diagnostics

EEG Breakthrough: LVIS Corporation Launches AI Platform That Simplifies Ambulatory Review for Effortless Clinical Workflows

New AI Tools Speed Up Diagnostics, With Higher Accuracy And Lower Cost

LVIS Corporation launches AI platform that simplifies ambulatory review for effortless clinical workflows

LVIS Adds Ambulatory EEG to NeuroMatch Platform

Breaking New Ground in Alzheimer’s Care

Are AI-Powered Neurodiagnostic Solutions the New Frontier in Alzheimer’s Prevention?

LVIS NeuroMatch secures ISO 13485 certification

The EEG Revolution Is Finally Here: Brain Health Is Entering a New Era

NeuroMatch EEG diagnostics platform launches in US

NeuroMatch EEG diagnostics platform launches in US

AI-Powered NeuroMatch Pro Enhances EEG Diagnostics with Seizure and Spike Detection

LVIS launches Neuromatch Access in US, Korea as EEG diagnostic

NeuroMatch EEG diagnostics platform launches in US

LVIS Corporation Unveils Cloud-Based Platform for EEG Diagnostics

Join the LVIS NeuroMatch Newsletter

Subscribe to our newsletter and stay updated on the latest innovations, awards, and events you won't want to miss!

We have an international team with our headquarters located in Palo Alto, California, USA, and offices in Gangnam, Seoul, Korea, and Daegu, Korea.

Palo Alto, California

Gangnam, Seoul, Korea

Daegu, Korea

© 2026 LVIS Corporation. All Rights Reserved.

Terms Of Service

Privacy Policy

LVIS has obtained regulatory clearance for NeuroMatch in the United States and Korea.
NeuroMatch United States FDA Clearance #: K241390
NeuroMatch Korea MFDS Clearance #: License number 23-4685
Certain features shown are not yet cleared in the United States.